Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting

[1]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  C. Teunissen,et al.  Pre-analytical stability of serum biomarkers for neurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1 , 2022, Clinical chemistry and laboratory medicine.

[3]  K. Blennow,et al.  Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[4]  E. Diamandis,et al.  Uncovering the Depths of the Human Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein Detection and Quantification , 2021, Molecular & cellular proteomics : MCP.

[5]  B. Mollenhauer,et al.  Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders , 2021, Movement disorders : official journal of the Movement Disorder Society.

[6]  F. Zipp,et al.  The potential of serum neurofilament as biomarker for multiple sclerosis , 2021, Brain : a journal of neurology.

[7]  G. Halliday,et al.  Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson’s Disease Patients , 2021, Journal of Parkinson's disease.

[8]  R. Lanzenberger,et al.  Seven day pre-analytical stability of serum and plasma neurofilament light chain , 2021, Scientific Reports.

[9]  Li-Jun Jiang,et al.  Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis , 2021, Translational neurodegeneration.

[10]  Byeong-Chae Kim,et al.  Plasma contact factors as novel biomarkers for diagnosing Alzheimer’s disease , 2021, Biomarker research.

[11]  K. Blennow,et al.  Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration , 2021, Alzheimer's & dementia.

[12]  B. Bloem,et al.  Reader response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease , 2020, Neurology.

[13]  W. M. van der Flier,et al.  Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology , 2020, Alzheimer's Research & Therapy.

[14]  K. Blennow,et al.  Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease , 2020, Translational Psychiatry.

[15]  K. Blennow,et al.  Comparing Glial Fibrillary Acidic Protein (GFAP) in Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults , 2020, Frontiers in Neurology.

[16]  A. Singleton,et al.  Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression , 2020, Movement disorders : official journal of the Movement Disorder Society.

[17]  K. Blennow,et al.  Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. , 2020, Journal of Alzheimer's disease : JAD.

[18]  K. Blennow,et al.  NfL as a biomarker for neurodegeneration and survival in Parkinson disease , 2020, Neurology.

[19]  B. Bloem,et al.  Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy. , 2020, Parkinsonism & related disorders.

[20]  N. Keong,et al.  Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease , 2020, Molecular Neurodegeneration.

[21]  Yen-Hsiang Chang,et al.  Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease , 2020, Frontiers in Aging Neuroscience.

[22]  T. Parkner,et al.  Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults , 2020, Scandinavian journal of clinical and laboratory investigation.

[23]  G. Frisoni,et al.  Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[24]  N. Keong,et al.  Plasma ubiquitin C-terminal hydrolase L1 levels reflect disease stage and motor severity in Parkinson’s disease , 2020, Aging.

[25]  Xiao-Min Wang,et al.  Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease , 2020, Journal of Neuroinflammation.

[26]  Bo-Ching Lee,et al.  Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease. , 2019, Journal of Parkinson's disease.

[27]  H. Berendse,et al.  CSF or serum neurofilament light added to α‐Synuclein panel discriminates Parkinson's from controls , 2019, Movement disorders : official journal of the Movement Disorder Society.

[28]  M. DeMarco,et al.  The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis , 2019, Alzheimer's & dementia.

[29]  N. Martin,et al.  Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[30]  Kai-Chien Yang,et al.  Blood NfL , 2019, Neurology.

[31]  D. Erskine,et al.  Antibodies against alpha‐synuclein: tools and therapies , 2019, Journal of neurochemistry.

[32]  Zheyu Xu,et al.  Plasma alpha‐synuclein detected by single molecule array is increased in PD , 2019, Annals of clinical and translational neurology.

[33]  G. Halliday,et al.  Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease , 2018, Scientific Reports.

[34]  R. Barker,et al.  The clinical heterogeneity of Parkinson's disease and its therapeutic implications , 2018, The European journal of neuroscience.

[35]  K. Blennow,et al.  Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod , 2018, Multiple sclerosis.

[36]  J. Trojanowski,et al.  The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer’s disease , 2018, PloS one.

[37]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[38]  M. Staufenbiel,et al.  Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases , 2016, Neuron.

[39]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[40]  Kevin K. W. Wang,et al.  Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker , 2015, Trends in Neurosciences.

[41]  Peter Diggle,et al.  A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease , 2013, Scientific Reports.

[42]  Tatsuki Koyama,et al.  Accuracy and reproducibility of a multiplex immunoassay platform: a validation study. , 2011, Journal of immunological methods.

[43]  F. Barrero,et al.  Plasma α‐synuclein in patients with Parkinson's disease with and without treatment , 2010, Movement disorders : official journal of the Movement Disorder Society.

[44]  R. Barbour,et al.  Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood , 2008, Neurodegenerative Diseases.

[45]  P. Lee,et al.  The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy , 2006, Journal of Neural Transmission.

[46]  L. Rosengren,et al.  Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple‐system atrophy compared with Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.